Mitomycin C: Biological effects and use in refractive surgery

Cornea

Volumn 31, Issue 3, 2012, Pages 311-321

  Santhiago, Marcony R ^a,b   Netto, Marcelo V ^b   Wilson, Steven E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Haze; Mitomycin C; Myofibroblasts; Photorefractive keratectomy; Wound healing

Indexed keywords

INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MITOMYCIN C; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; APOPTOSIS; CORNEA CELL; CORNEA DISEASE; CORNEA TRANSPLANTATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; KERATOMILEUSIS; LONG TERM CARE; LOW DRUG DOSE; MYOFIBROBLAST; MYOPIA; PENETRATING KERATOPLASTY; PHOTOREFRACTIVE KERATECTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; WOUND HEALING;

ALKYLATING AGENTS; ANIMALS; CHEMOTHERAPY, ADJUVANT; CORNEAL DISEASES; CORNEAL SURGERY, LASER; HUMANS; MITOMYCIN; RABBITS; WOUND HEALING;

EID: 84857236208     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31821e429d     Document Type: Review

References (189)

1. Hata T, Hoshi T, Kanamori K, et al. Mitomycin, a new antibiotic from Streptomyces. I. J Antibiot. 1956;9:141-146.
2. Shiraha Y, Sakai K, Teranaka T. Clinical trials of mitomycin C, a new antitumor antibiotic; preliminary report of results obtained in 82 consecutive cases in the field of general surgery. Antibiot Annu. 1959;6: 533-540.
3. Wakaki S. Recent advance in research on antitumor mitomycins. Cancer Chemother Rep. 1961;13:79-86.
4. Bligh HF, Bartoszek A, Robson CN, et al. Activation of mitomycin C by NADPH:cytochrome p-450 reductase. Cancer Res. 1990;50:7789-7792.
5. Crowston JG, Chang LH, Constable PH, et al. Apoptosis gene expression and death receptor signalling in mitomycin- C-treated human Tenon capsule fibroblasts. Invest Ophthalmol Vis Sci. 2002;43:692-699. (Pubitemid 34184486)
6. Cummings J, Spanswick VJ, TomaszM, et al. Enzymology ofmitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development. Biochem Pharmacol. 1998;56:405-414. (Pubitemid 28468576)
7. Wang SL, Han JF, He XY, et al. Genetic variation of human cytochrome p450 reductase as a potential biomarker for mitomycin C-induced cytotoxicity. Drug Metab Dispos. 2007;35:176-179.
8. Islaih M, Halstead BW, Kadura IA, et al. Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicals. Mutat Res. 2005;578:100-116. (Pubitemid 41395315)
9. Mladenov E, Tsaneva I, Anachkova B. Activation of the S phase DNA damage checkpoint by mitomycin C. J Cell Physiol. 2007;211:468-476. (Pubitemid 46580100)
10. Tomasz M. Mitomycin C: small, fast and deadly (but very selective). Chem Biol. 1995;2:575-579.
11. Szybalski W, Lyer VN. Crosslinking of DNA by enzymatic or activated mitomycins and porfiromycins, bifunctionally alkylating antibiotics. Fed Proc. 1964;23:946-957.
12. Galm U, Hager MH, Van Lanen SG, et al. Antitumor antibiotics: bleomycin, enediynes, and mitomycin. Chem Rev. 2005;105:739-758. (Pubitemid 40351639)
13. Fujita T, Tamura T, Yamada H, et al. Pharmacokinetics of mitomycin C (MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice. J Drug Target. 1997;4:289-296. (Pubitemid 27239016)
14. Reddy MV, Randerath K. 32P-analysis of DNA adducts in somatic and reproductive tissues of rats treated with the anticancer antibiotic, mitomycin C. Mutat Res. 1987;179:75-88. (Pubitemid 17100600)
15. Warren AJ,Maccubbin AE, Hamilton JW. Detection of mitomycin C-DNA adducts in vivo by 32P-postlabeling: time course for formation and removal of adducts and biochemical modulation. Cancer Res. 1998;58: 453-461. (Pubitemid 28087406)
16. Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs. 1990;1:5-13.
17. Pritsos CA, Sartorelli AC. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics. Cancer Res. 1986;46: 3528-3532. (Pubitemid 16096902)
18. Pogrebniak HW, Matthews W, Pass HI. Chemotherapy amplifies production of tumor necrosis factor. Surgery. 1991;110:231-237.
19. Goeptar AR, Groot EJ, Scheerens H, et al. Cytotoxicity of mitomycin C and Adriamycin in freshly isolated rat hepatocytes: the role of cytochrome p450. Cancer Res. 1994;54:2411-2418. (Pubitemid 24138733)
20. Abraham LM, Selva D, Casson R, et al. Mitomycin: clinical applications in ophthalmic practice. Drugs. 2006;66:321-340. (Pubitemid 46291768)
21. Akarsu C, Onol M, Hasanreisoglu B. Effects of thick Tenon's capsule on primary trabeculectomy with mitomycin-C. Acta Ophthalmol Scand. 2003;81:237-241. (Pubitemid 36806260)
22. Oguz H. Mitomycin C and pterygium excision. Ophthalmology. 2003; 110:2257-2258.
23. Lee JS, Oum BS, Lee SH. Mitomycin C influence on inhibition of cellular proliferation and subsequent synthesis of type I collagen and laminin in primary and recurrent pterygia. Ophthalmic Res. 2001;33: 140-146. (Pubitemid 32424538)
24. Watanabe J, Sawaguchi S, Fukuchi T, et al. Effects of mitomycin C on the expression of proliferating cell nuclear antigen after filtering surgery in rabbits. Graefes Arch Clin Exp Ophthalmol. 1997;235:234-240.
25. Pinilla I, Larrosa JM, Polo V, et al. Subconjunctival injection of low doses of mitomycin C: effects on fibroblast proliferation. Ophthalmologica. 1998;212:306-309. (Pubitemid 28370961)
26. Netto MV, Mohan RR, Ambrósio R Jr, et al. Wound healing in the cornea: a review of refractive surgery complications and new prospects for therapy. Cornea. 2005;24:509-522. (Pubitemid 40885027)
27. Mohan RR, Liang Q, Kim WJ, et al. Apoptosis in the cornea: further characterization of Fas/Fas ligand system. Exp Eye Res. 1997;65:575-589. (Pubitemid 27454957)
28. Mohan RR, Kim WJ, Mohan RR, et al. Bone morphogenic proteins 2 and 4 and their receptors in the adult human cornea. Invest Ophthalmol Vis Sci. 1998;39:2626-2636. (Pubitemid 28558221)
29. Wilson SE, He YG, Weng J, et al. Epithelial injury induces keratocyte apoptosis: hypothesized role for the interleukin-1 system in the modulation of corneal tissue organization and wound healing. Exp Eye Res. 1996;62:325-327.
30. Mohan RR, Mohan RR, Kim WJ, et al. Modulation of TNF-alpha induced apoptosis in corneal fibroblasts by transcription factor NF-kb. Invest Ophthalmol Vis Sci. 2000;41:1327-1334.
31. Wilson SE, Chen L, Mohan RR, et al. Expression of HGF, KGF, EGFand receptor messenger RNAs following corneal epithelial wounding. Exp Eye Res. 1999;68:377-397. (Pubitemid 29185432)
32. Tuominen IS, Tervo TM, Teppo AM, et al. Human tear fluid PDGF-BB, TNF-alpha and TGF-beta1 vs corneal haze and regeneration of corneal epithelium and subbasal nerve plexus after PRK. Exp Eye Res. 2001;72: 631-641. (Pubitemid 32977209)
33. Jester JV, Huang J, Petroll WM, et al. TGF beta induced myofibroblast differentiation of rabbit keratocytes requires synergistic TGF beta, PDGF and integrin signaling. Exp Eye Res. 2002;75:645-657. (Pubitemid 36034629)
34. Zieske JD, Guimaraes SR, Hutcheon AE. Kinetics of keratocyte proliferation in response to epithelial debridement. Exp Eye Res. 2001; 72:33-39. (Pubitemid 32056718)
35. Wilson SE. Molecular cell biology for the refractive corneal surgeon: programmed cell death and wound healing. J Refract Surg. 1997;13: 171-175. (Pubitemid 27203276)
36. Helena MC, Baerveldt F, Kim W-J, et al. Keratocyte apoptosis after corneal surgery. Invest Ophthalmol Vis Sci. 1998;39:276-283. (Pubitemid 28093862)
37. Wilson SE, Mohan RR, Ambrosio R, et al. Corneal injury: a relatively pure model of stromal-epithelial interactions in wound healing. Prog Retin Eye Res. 2001;20:625-637.
38. Wilson SE. Analysis of the keratocyte apoptosis, keratocyte proliferation, and myofibroblast transformation responses after photorefractive keratectomy and laser in situ keratomileusis. Trans Am Ophthalmol Soc. 2002;100:411-433. (Pubitemid 37039381)
39. Jester JV, Barry PA, Lind GJ, et al. Corneal keratocytes: in situ and in vitro organization of cytoskeletal contractile proteins. Invest Ophthalmol Vis Sci. 1994;35:730-743. (Pubitemid 24078133)
40. Wilson SE, Kim WJ. Keratocyte apoptosis: implications on corneal wound healing, tissue organization, and disease. Invest Ophthalmol Vis Sci. 1998;39:220-226.
41. Masur SK, Dewal HS, Dinh TT, et al. Myofibroblasts differentiate from fibroblasts when plated at low density. Proc Natl Acad Sci U S A. 1996; 93:4219-4223. (Pubitemid 26144266)
42. Jester JV, Huang J, Barry-Lane PA, et al. Transforming growth factor (beta)-mediated corneal myofibroblast differentiation requires actin and fibronectin assembly. Invest Ophthalmol Vis Sci. 1999;40:1959-1967. (Pubitemid 29365158)
43. Jester JV, Petroll WM, Cavanagh HD. Corneal stromal wound healing in refractive surgery: the role of myofibroblasts. Prog Retin Eye Res. 1999; 18:311-356. (Pubitemid 29092610)
44. O'Brien T, Li Q, Ashraf MF, et al Inflammatory response in the early stages of wound healing after excimer laser keratectomy. Arch Ophthalmol. 1998;116:1470-1474. (Pubitemid 28520667)
45. Wilson SE,Mohan RR, Netto MV, et al RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing. Invest Ophthalmol Vis Sci. 2004;45:2201-2211. (Pubitemid 38902590)
46. Wilson SE, Walker JW, Chwang EL, et al. Hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), their receptors, FGF receptor-2, and the cells of the cornea. Invest Ophthalmol Vis Sci. 1993;34: 2544-2561. (Pubitemid 23206485)
47. Wilson SE, He Y-G, Weng J, et al. Effect of epidermal growth factor, hepatocyte growth factor, and keratinocyte growth factor, on proliferation, motility, and differentiation of human corneal epithelial cells. Exp Eye Res. 1994;59:665-678.
48. Kaur H, Chaurasia SS, Agrawal V, et al. Corneal myofibroblast viability: opposing effects of IL-1 and TGF beta-1. Exp Eye Res. 2009;89: 152-158.
49. Barbosa FL, Chaurasia SS, Kaur H, et al. Stromal interleukin-1 expression in the cornea after haze-associated injury. Exp Eye Res. 2010; 91:456-461.
50. Stramer BM, Zieske JD, Jung JC, et al. Molecular mechanisms controlling the fibrotic repair phenotype in cornea: implications for surgical outcomes. Invest Ophthalmol Vis Sci. 2003;44:4237-4246. (Pubitemid 37186257)
51. Mohan RR, Hutcheon AE, Choi R, et al. Apoptosis, necrosis, proliferation, and myofibroblast generation in the stroma following LASIK and PRK. Exp Eye Res. 2003;76:71-87. (Pubitemid 36268717)
52. Barbosa FL, Chaurasia S, Cutler A, et al. Corneal myofibroblast generation from bone marrow-derived cells. Exp Eye Res. 2010;91: 92-96.
53. Rajan MS, Jaycock P, O'Brart D, et al. A long-term study of photorefractive keratectomy; 12-year followup. Ophthalmology. 2004; 111:1813-1824. (Pubitemid 39311831)
54. Hersh PS, Stulting RD, Steinert RF, et al. Results of phase III excimer laser photorefractive keratectomy for myopia. The Summit PRK Study Group. Ophthalmology. 1997;104:1535-1553. (Pubitemid 28053450)
55. El-Maghraby A, Salah T, Waring GO III, et al. Randomized bilateral comparison of excimer laser in situ keratomileusis and photorefractive keratectomy for 2.50 to 8.00 diopters of myopia. Ophthalmology. 1999; 106:447-457. (Pubitemid 30191577)
56. Moller-Pedersen T, Cavanagh HD, Petroll WM, et al. Corneal haze development after PRK is regulated by volume of stromal tissue removal. Cornea. 1998;17:627-639. (Pubitemid 28511910)
57. Lipshitz I, Loewenstein A, Varssano D, et al. Late onset corneal haze after photorefractive keratectomy for moderate and high myopia. Ophthalmology. 1997;104:369-373.
58. Kuo IC, Lee SM, Hwang DG. Late-onset corneal haze and myopic regression after photorefractive keratectomy (PRK). Cornea. 2004;23: 350-355. (Pubitemid 38544050)
59. Kapadia MS, Wilson SE. One-year results of PRK in low and moderate myopia: fewer than 0.5% of eyes lose two or more lines of vision. Cornea. 2000;19:180-184. (Pubitemid 30140821)
60. Vinciguerra P, Azzolini M, Airaghi P, et al. Effect of decreasing surface and interface irregularities after photorefractive keratectomy and laser in situ keratomileusis on optical and functional outcomes. J Refract Surg. 1998;14:S199-S203. (Pubitemid 28193634)
61. Serrao S, Lombardo M, Mondini F. Photorefractive keratectomy with and without smoothing: a bilateral study. J Refract Surg. 2003;19:58-64. (Pubitemid 36126028)
62. Netto MV, Mohan RR, Sinha S, et al. Stromal haze, myofibroblasts, and surface irregularity after PRK. Exp Eye Res. 2006;82:788-797. (Pubitemid 43170879)
63. Boote C, Dennis S, Newton RH, et al. Collagen fibrils appear more closely packed in the prepupillary cornea: optical and biomechanical implications. Invest Ophthalmol Vis Sci. 2003;44:2941-2948. (Pubitemid 36759756)
64. Conrad GW, Funderburgh JL. Eye development and the appearance and maintenance of corneal transparency. Trans Kans Acad Sci. 1992;95:34-38.
65. Maurice DM. The transparency of the corneal stroma. Vision Res. 1970; 10:107-108.
66. Michelacci YM. Collagens and proteoglycans of the corneal extracellular matrix. Braz J Med Biol Res. 2003;36:1037-1046. (Pubitemid 37080914)
67. Kurosaka H, Kurosaka D, Kato K, et al. Transforming growth factor-beta 1 promotes contraction of collagen gel by bovine corneal fibroblasts through differentiation of myofibroblasts. Invest Ophthalmol Vis Sci. 1998;39:699-704. (Pubitemid 28207463)
68. Piatigorsky J. Review: a case for corneal crystallins. J Ocul Pharmacol Ther. 2000;16:173-180. (Pubitemid 30235976)
69. Jester JV, Moller-Pedersen T, Huang J, et al. The cellular basis of corneal transparency: evidence for corneal crystallins'. J Cell Sci. 1999;112:613-622. (Pubitemid 29141981)
70. Maltseva O, Folger P, Zekaria D, et al. Fibroblast growth factor reversal of the corneal myofibroblast phenotype. Invest Ophthalmol Vis Sci. 2001;42:2490-2495. (Pubitemid 32954853)
71. Jester JV, Ho-Chang J. Modulation of cultured corneal keratocyte phenotype by growth factors/cytokines control in vitro contractility and extracellular matrix contraction. Exp Eye Res. 2003;77:581-592. (Pubitemid 37188733)
72. Dawson DG, Edelhauser HF, Grossniklaus HE. Long-term histopathologic findings in human corneal wounds after refractive surgical procedures. Am J Ophthalmol. 2005;139:168-178. (Pubitemid 40094856)
73. Tang X, Liao Z. A clinical study of correlation between ablation depth and corneal subepithelial haze after photorefractive keratectomy. Zhonghua Yan Ke Za Zhi. 1997;33:204-206.
74. Vinciguerra P, Azzolini M, Radice P, et al. A method for examining surface and interface irregularities after photorefractive keratectomy and laser in situ keratomileusis: predictor of optical and functional outcomes. J Refract Surg. 1998;14:S204-S206. (Pubitemid 28193635)
75. Nakamura Y, Sotozono C, Kinoshita S. The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res. 2001;72:511-517. (Pubitemid 32977221)
76. Thomas KE, Brunstetter T, Rogers S, et al. Astigmatism: risk factor for postoperative corneal haze in conventional myopic photorefractive keratectomy. J Cataract Refract Surg. 2008;34:2068-2072.
77. Stojanovic A, Nitter TA. Correlation between ultraviolet radiation level and the incidence of late-onset corneal haze after photorefractive keratectomy. J Cataract Refract Surg. 2001;27:404-410. (Pubitemid 32233839)
78. Shah SS, Kapadia MS, Meisler DM, et al. Photorefractive keratectomy using the summit SVS Apex laser with or without astigmatic keratotomy. Cornea. 1998;17:508-516. (Pubitemid 28420682)
79. Funderburgh JL, Mann MM, Funderburgh ML. Keratocyte phenotype mediates proteoglycan structure: a role for fibroblasts in corneal fibrosis. J Biol Chem. 2003;278:45629-45637. (Pubitemid 37432705)
80. Siganos DS, Katsanevaki VJ, Pallikaris IG. Correlation of subepithelial haze and refractive regression 1 month after photorefractive keratectomy for myopia. J Refract Surg. 1999;15:338-342. (Pubitemid 29244886)
81. Netto MV, Mohan RR, Sinha S, et al. Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits. J Refract Surg. 2006; 22:562-574.
82. Wilson SE, Chaurasia SS, Medeiros FW. Apoptosis in the initiation, modulation and termination of the corneal wound healing response. Exp Eye Res. 2007;85:305-311. (Pubitemid 47259060)
83. Schipper I, Suppelt C, Gebbers JO. Mitomycin C reduces scar formation after excimer laser (193 nm) photorefractive keratectomy in rabbits. Eye. 1997;11:649-655. (Pubitemid 27499820)
84. Xu H, Liu S, Xia X, et al. Mitomycin C reduces haze formation in rabbits after excimer laser photorefractive keratectomy. J Refract Surg. 2001;17: 342-349. (Pubitemid 32487872)
85. Carones F, Vigo L, Scandola E, et al. Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy. J Cataract Refract Surg. 2002;28:2088-2095. (Pubitemid 36026085)
86. Porges Y, Ben-Haim O, Hirsh A, et al. Phototherapeutic keratectomy with mitomycin C for corneal haze following photorefractive keratectomy for myopia. J Refract Surg. 2003;19:40-43. (Pubitemid 36126024)
87. Camellin M. Laser epithelial keratomileusis with mitomycin C: indications and limits. J Refract Surg. 2004;20:S693-S698. (Pubitemid 39299520)
88. Argento C, Cosentino MJ, Ganly M. Comparison of laser epithelial keratomileusis with and without the use of mitomycin C. J Refract Surg. 2006;22:782-786. (Pubitemid 44595123)
89. Bedei A, Marabotti A, Giannecchini I, et al. Photorefractive keratectomy in high myopic defects with or without intraoperative mitomycin C: 1-year results. Eur J Ophthalmol. 2006;16:229-234. (Pubitemid 43874392)
90. Gambato C, Ghirlando A, Moretto E, et al. Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes. Ophthalmology. 2005;112:208-218. (Pubitemid 40202553)
91. Shalaby A, Kaye GB, Gimbel HV. Mitomycin C in photorefractive keratectomy. J Refract Surg. 2009;25:S93-S97.
92. Leccisotti A. Mitomycin-C in hyperopic photorefractive keratectomy. J Cataract Refract Surg. 2009;35:682-687.
93. Anbar R, Malta JB, Barbosa JB, et al. Photorefractive keratectomy with mitomycin-C for consecutive hyperopia after radial keratotomy. Cornea. 2009;28:371-374.
94. Koch DD, Maloney R, Hardten DR, et al. Wavefront-guided photorefractive keratectomy in eyes with prior radial keratotomy: a multicenter study. Ophthalmology. 2009;116:1688-1696.
95. Wallau AD, Campos M. One-year outcomes of a bilateral randomised prospective clinical trial comparing PRK with mitomycin C and LASIK. Br J Ophthalmol. 2009;93:1634-1638.
96. Barreto J Jr, Netto MV, Reis A, et al. Topography-guided (NIDEK customized aspheric treatment zone) photorefractive keratectomy with mitomycin C after penetrating keratoplasty for keratoconus: case report. J Refract Surg. 2009;25:S131-S135.
97. Netto MV, Chalita MR, Krueger RR. Corneal haze following PRK with mitomycin C as a retreatment versus prophylactic use in the contralateral eye. J Refract Surg. 2007;23:96-98. (Pubitemid 46122704)
98. Lee DH, Chung HS, Jeon YC, et al. Photorefractive keratectomy with intraoperative mitomycin-C application. J Cataract Refract Surg. 2005; 31:2293-2298. (Pubitemid 43212917)
99. Vigo L, Scandola E, Carones F. Scraping and mitomycin C to treat haze and regression after photorefractive keratectomy for myopia. J Refract Surg. 2003;19:449-454. (Pubitemid 36890566)
100. Azar DT, Jain S. Topical MMC for subepithelial fibrosis after refractive corneal surgery. Ophthalmology. 2001;108:239-240. (Pubitemid 32115945)
101. Raviv T, Majmudar PA, Dennis RF, et al. Mytomycin-C for post-PRK corneal haze. J Cataract Refract Surg. 2000;26:1105-1106.
102. Sadeghi HM, Seitz B, Hayashi S, et al. In vitro effects of mitomycin-C on human keratocytes. J Refract Surg. 1998;14:534-540. (Pubitemid 28460914)
103. Majmudar PA, Forstot SL, Dennis RF, et al. Topical mitomycin-C for subepithelial fibrosis after refractive corneal surgery. Ophthalmology. 2000;107:89-94. (Pubitemid 30210188)
104. Virasch VV, Majmudar PA, Epstein RJ, et al. Reduced application time for prophylactic mitomycin C in photorefractive keratectomy. Ophthalmology. 2010;117:885-889.
105. Thornton I, Xu M, Krueger RR. Comparison of standard (0.02%) and low dose (0.002%) mitomycin C in the prevention of corneal haze following surface ablation for myopia. J Refract Surg. 2008;24:S68-S76.
106. Song JS, Kim JH, Yang M, et al. Concentrations of mitomycin C in rabbit corneal tissue and aqueous humor after topical administration. Cornea. 2006;25:S20-S23.
107. Song JS, Kim JH, Yang M, et al. Mitomycin C concentration in cornea and aqueous humor and apoptosis in the stroma after topical mitomycin- C application. Effects of mitomycin-C application time and concentration. Cornea. 2007;26:461-467. (Pubitemid 46684388)
108. Lacayo GO III, Majmudar PA. How and when to use mitomycin-C in refractive surgery. Curr Opin Ophthalmol. 2005;16:256-259. (Pubitemid 41073310)
109. Teus MA, de Benito-Llopis L, AlióJL. Mitomycin C in corneal refractive surgery. Surv Ophthalmol. 2009;54:487-502.
110. Kim TI, Tchah H, Lee SA, et al. Apoptosis in keratocytes caused by mitomycin C. Invest Ophthalmol Vis Sci. 2003;44:1912-1917. (Pubitemid 36522777)
111. Kim TI, Pak JH, Lee SY, et al. Mitomycin C-induced reduction of keratocytes and fibroblasts after photorefractive keratectomy. Invest Ophthalmol Vis Sci. 2004;45:2978-2984. (Pubitemid 39121825)
112. Chang SW. Corneal keratocyte apoptosis following topical intraoperative mitomycin C in rabbits. J Refract Surg. 2005;21:446-453.
113. Rubinfeld RS, Pfister RR, Stein RM, et al. Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology. 1992;99: 1647-1654.
114. Safianik B, Ben-Zion I,Garzozi HJ. Serious corneoscleral complications after pterygium excision with mitomycin C. Br J Ophthalmol. 2002;86:357-358. (Pubitemid 34206358)
115. Vesaluoma M, Perez-Santonja J, Petroll WM, et al. Corneal stromal changes induced by myopic LASIK. Invest Ophthalmol Vis Sci. 2000;41:369-376. (Pubitemid 30080437)
116. Erie JC, Patel SV, McLaren JW, et al. Keratocyte density in the human cornea after photorefractive keratectomy. Arch Ophthalmol. 2003;121: 770-776. (Pubitemid 36676212)
117. Dougherty PJ, Hardten DR, Lindstrom RL. Corneoscleral melt after pterygium surgery using a single intraoperative application of mitomycin-C. Cornea. 1996;15:537-540. (Pubitemid 26271794)
118. Midena E, Gambato C, Miotto S, et al. Long-term effects on corneal keratocytes of mitomycin C during photorefractive keratectomy: a randomized contralateral eye confocal microscopy study. J Refract Surg. 2007;23:S1011-S1014. (Pubitemid 350175100)
119. Roh DS, Funderburgh JL. Impact on the corneal endothelium of mitomycin C during photorefractive keratectomy. J Refract Surg. 2009; 25:894-897.
120. McDermott ML, Wang J, Shin DH. Mitomycin and the human corneal endothelium. Arch Ophthalmol. 1994;112:533-537. (Pubitemid 24114076)
121. Torres RM, Merayo-Lloves J, Daya SM, et al. Presence of mitomycin-C in the anterior chamber after photorefractive keratectomy. J Cataract Refract Surg. 2006;32:67-71. (Pubitemid 43330051)
122. Roh DS, Cook AL, Rhee SS, et al. DNA cross-linking, double-strand breaks and apoptosis in corneal endothelial cells after a single exposure to mitomycin-C. Invest Ophthalmol Vis Sci. 2008;49:4837-4843.
123. Garweg JG, Wegmann-Burns M, Goldblum D. Effects of daunorubicin, mitomycin C, azathioprine and cyclosporin A on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines. Graefes Arch Clin Exp Ophthalmol. 2006;244:382-389.
124. Wu KY, Hong SJ, Huang HT, et al. Toxic effects of mitomycin-C on cultured corneal keratocytes and endothelial cells. J Ocul Pharmacol Ther. 1999;15:401-411.
125. Diakonis VF, Pallikaris A, Kymionis GD, et al. Alterations in endothelial cell density after photorefractive keratectomy with adjuvant mitomycin. Am J Ophthalmol. 2007;144:99-103.
126. Goldsberry DH, Epstein RJ, Majmudar PA, et al. Effect of mitomycin C on the corneal endothelium when used for corneal subepithelial haze prophylaxis following photorefractive keratectomy. J Refract Surg. 2007; 23:724-727. (Pubitemid 47424681)
127. Nassaralla BA, McLeod SD, Nassaralla JJ Jr. Prophylactic mitomycin C to inhibit corneal haze after photorefractive keratectomy for residual myopia following radial keratotomy. J Refract Surg. 2007;23:226-232. (Pubitemid 46452466)
128. Nassiri N, Farahangiz S, Rahnavardi M, et al. Corneal endothelial cell injury induced by mitomycin-C in photorefractive keratectomy: nonrandomized controlled trial. J Cataract Refract Surg. 2008;34:902-908. (Pubitemid 351695506)
129. Morales AJ, Zadok D, Mora-Retana R, et al. Intraoperative mitomycin and corneal endothelium after photorefractive keratectomy. Am J Ophthalmol. 2006;142:400-404. (Pubitemid 44691754)
130. AlióJL,Muftuoglu O, Ortiz D, et al. Ten-year follow-up of photorefractive keratectomy for myopia of less than 26 diopters. Am J Ophthalmol. 2008; 145:29-36.
131. AlióJL, Muftuoglu O, Ortiz D, et al. Ten-year follow-up of photorefractive keratectomy for myopia of more than 26 diopters. Am J Ophthalmol. 2008;145:37-45.
132. PietiläJ,Mäkinen P, Uusitalo H. Repeated photorefractive keratectomy for undercorrection and regression. J Refract Surg. 2002;18:155-161. (Pubitemid 34727808)
133. Haw WW, Manche EE. Excimer laser retreatment of residual myopia following photoastigmatic refractive keratectomy for compound myopic astigmatism. J Cataract Refract Surg. 2000;26:660-667. (Pubitemid 30332458)
134. Rozśval P, FeuermannováA. Retreatment after photorefractive keratectomy for low myopia. Ophthalmology. 1998;105:1189-1192.
135. Beerthuizen JJ, Siebelt E. Surface ablation after laser in situ keratomileusis: retreatment on the flap. J Cataract Refract Surg. 2007; 33:1376-1380. (Pubitemid 47088149)
136. Neira-Zalentein W, Moilanen JAO, Tuisku IS, et al. Photorefractive keratectomy retreatment after LASIK. J Refract Surg. 2008;24:710-712.
137. Carones F, Vigo L, Carones AV, et al. Evaluation of photorefractive keratectomy retreatments after regressed myopic laser in situ keratomileusis. Ophthalmology. 2001;108:1732-1737. (Pubitemid 32905925)
138. Shaikh NM, Wee CE, Kaufman SC. The safety and efficacy of photorefractive keratectomy after laser in situ keratomileusis. J Refract Surg. 2005;21:353-358. (Pubitemid 41026060)
139. Srinivasan S, Drake A, Herzig S. Photorefractive keratectomy with 0.02% mitomycin C for treatment of residual refractive errors after LASIK. J Refract Surg. 2008;24:S64-S67.
140. Liu A, Manche EE. Visually significant haze after retreatment with photorefractive keratectomy with mitomycin-C following laser in situ keratomileusis. J Cataract Refract Surg. 2010;36:1599-1601.
141. Ambrósio R Jr, Wilson S. LASIK vs LASEK vs PRK: advantages and indications. Semin Ophthalmol. 2003;18:2-10. (Pubitemid 36993547)
142. Teus MA, de Benito-Llopis L, Sánchez-Pina JM. LASEK versus LASIK for the correction of moderate myopia. Optom Vis Sci. 2007;84:605-610. (Pubitemid 47075610)
143. de Benito-Llopis L, Teus MA, Gil-Cazorla R, et al. Comparison between femtosecond laser-assisted sub-Bowman keratomileusis vs laser subepithelial keratectomy to correct myopia. Am J Ophthalmol. 2009;148: 830-836.
144. Vinciguerra P, Camesasca FI, Randazzo A. One-year results of butterfly laser epithelial keratomileusis. J Refract Surg. 2003;19: S223-S226.
145. Partal AE, Rojas MC, Manche EE. Analysis of the efficacy, predictability and safety of LASEK for myopia and myopic astigmatism using the Technolas 217 excimer laser. J Cataract Refract Surg. 2004;30: 2138-2144. (Pubitemid 39330672)
146. Taneri S, Feit R, Azar DT. Safety, efficacy and stability indices of LASEK correction in moderate myopia and astigmatism. J Cataract Refract Surg. 2004;30:2130-2137. (Pubitemid 39330671)
147. Azar DT, Ang RT, Lee JB, et al. Laser subepithelial keratomileusis: electron microscopy and visual outcomes of flap photorefractive keratectomy. Curr Opin Ophthalmol. 2001;12:323-328. (Pubitemid 32751692)
148. Dastjerdi MH, Soong HK. LASEK (laser subepithelial keratomileusis). Curr Opin Ophthalmol. 2002;13:261-263. (Pubitemid 34925762)
149. Vinciguerra P, Camesasca FI. Butterfly laser epithelial keratomileusis for myopia. J Refract Surg. 2002;18:S371-S373.
150. Feit R, Taneri S, Azar DT, et al. LASEK results. Ophthalmol Clin North Am. 2003;16:127-135. (Pubitemid 36384134)
151. Camellin M. Laser epithelial keratomileusis for myopia. J Refract Surg. 2003;19:666-670. (Pubitemid 37443266)
152. Taneri S, Zieske JD, Azar DT. Evolution, techniques, clinical outcomes, and pathophysiology of LASEK: review of the literature. Surv Ophthalmol. 2004;49:576-602. (Pubitemid 39505335)
153. de Benito-Llopis L, Teus MA, Sánchez-Pina JM. Comparison between LASEK with mitomycin C and LASIK for the correction of myopia of 27.00 to 213.75 D. J Refract Surg. 2008;24:516-523. (Pubitemid 351668880)
154. de Benito-Llopis L, Teus MA, Sánchez-Pina JM, et al. Stability of laser epithelial keratomileusis with and without mitomycin C performed to correct myopia in thin corneas: a 15-month follow-up. Am J Ophthalmol. 2008;145:807-812.
155. Aydin B, Cagil N, Erdog? an S, et al. Effectiveness of laser-assisted subepithelial keratectomy without mitomycin-C for the treatment of high myopia. J Cataract Refract Surg. 2008;34:1280-1287. (Pubitemid 352024372)
156. Saeed A, O'Doherty M, O'Doherty J, et al. Laser-assisted subepithelial keratectomy retreatment after laser in situ keratomileusis. J Cataract Refract Surg. 2008;34:1736-1741.
157. Gabler B, von Mohrenfels CW, Herrmann W, et al. Laser-assisted subepithelial keratectomy enhancement of residual myopia after primary myopic LASEK: six-month results in 10 eyes. J Cataract Refract Surg. 2003;29:1260-1266. (Pubitemid 36935864)
158. Cagil N, Aydin B, Ozturk S, et al. Effectiveness of laser assisted subepithelial keratectomy to treat residual refractive errors after laser in situ keratomileusis. J Cataract Refract Surg. 2007;33:642-647. (Pubitemid 46505084)
159. de Benito-Llopis L, Teus MA. Efficacy of surface ablation retreatments using mitomycin C. Am J Ophthalmol. 2010;150:376-380.
160. Pallikaris IG, Katsanevaki VJ, Kalyvianaki MI, et al. Advances in subepithelial excimer refractive surgery techniques: Epi-LASIK. Curr Opin Ophthalmol. 2003;14:207-212. (Pubitemid 37011725)
161. Long Q, Chu R, Zhou X, et al. Correlation between TGF-beta 1 in tears and corneal haze following LASEK and Epi-LASIK. J Refract Surg. 2006;22:708-712. (Pubitemid 44380002)
162. Pallikaris IG, Naoumidi II, Kalyvianaki MI, et al. Epi-LASIK: comparative histological evaluation of mechanical and alcohol-assisted epithelial separation. J Cataract Refract Surg. 2003;29:1496-1501. (Pubitemid 37055850)
163. Gamaly TO, El Danasoury A, El Maghraby A. A prospective, randomized, contralateral eye comparison of epithelial laser in situ keratomileusis and photorefractive keratectomy in eyes prone to haze. J Refract Surg. 2007;23: S1015-S1020. (Pubitemid 350175101)
164. O'Doherty M, Kirwan C, O'Keeffe M, et al. Postoperative pain following epi-LASIK, LASEK, and PRK for myopia. J Refract Surg. 2007;23:133-138. (Pubitemid 46294473)
165. Kim ST, Koh JW, Yoon GJ, et al. Clinical outcomes of epi-LASIK: 1-year results of on- and off-flap procedures with and without mitomycin-C. Br J Ophthalmol. 2010;94:592-596.
166. Chen WL, Chang HW, Hu FR. In vivo confocal microscopic evaluation of corneal wound healing after epi-LASIK. Invest Ophthalmol Vis Sci. 2008;49:2416-2423.
167. Maloney RK, Chan WK, Steinert R, et al. A multicenter trial of photorefractive keratectomy for residual myopia after previous ocular surgery. Summit Therapeutic Refractive Study Group. Ophthalmology. 1995;102:1042-1052.
168. Stulting RD, Carr JD, Thompson KP, et al. Complications of laser in situ keratomileusis for the correction of myopia. Ophthalmology. 1999;106: 13-20.
169. Wilson SE. LASIK: management of common complications. Cornea. 1998;17:459-467. (Pubitemid 28420675)
170. Kapadia MS,Wilson SE. Transepithelial photorefractive keratectomy for treatment of thin flaps or caps following complicated laser in situ keratomileusis. Am J Ophthalmol. 1998;126:827-829. (Pubitemid 29001635)
171. Muller LT, Candal EM, Epstein RJ, et al. Transepithelial phototherapeutic keratectomy/photorefractive keratectomy with adjunctive mitomycin-C for complicated LASIK flaps. J Cataract Refract Surg. 2005;31:291-296. (Pubitemid 40379634)
172. Weisenthal RW, Salz J, Sugar A, et al. Photorefractive keratectomy for treatment of flap complications in laser in situ keratomileusis. Cornea. 2003;22:399-404. (Pubitemid 36759031)
173. Chalita MR, Roth AS, Krueger RR. Wavefront-guided surface ablation with prophylactic use of mitomycin C after a buttonhole laser in situ keratomileusis flap. J Refract Surg. 2004;20:176-181. (Pubitemid 38375299)
174. Lane HA, Swale JA, Majmudar PA. Prophylactic use of mitomycin-C in the management of a buttonholed LASIK flap. J Cataract Refract Surg. 2003;29:390-392. (Pubitemid 36278561)
175. Solomon R, Donnenfeld ED, Perry HD. Photorefractive keratectomy with mitomycin C for the management of a LASIK flap complication following a penetrating keratoplasty. Cornea. 2004;20:403-405. (Pubitemid 38544061)
176. Taneri S, Koch JM, Melki SA, et al. Mitomycin-C assisted photorefractive keratectomy in the treatment of buttonholed laser in situ keratomileusis flaps associated with epithelial ingrowth. J Cataract Refract Surg. 2005;31:2026-2030. (Pubitemid 41773182)
177. Kymionis GD, Portaliou DM, Karavitaki AE, et al. LASIK flap buttonhole treated immediately by PRK with mitomycin C. J Refract Surg. 2010;26:225-228.
178. Lazzaro DR, Haight DH, Belmont SC, et al. Excimer laser keratectomy for astigmatism occurring after penetrating keratoplasty. Ophthalmology. 1996;103:458-464. (Pubitemid 26085901)
179. Tuunanen TH, Ruusuvaara PJ, Uusitalo RJ, et al. Photoastigmatic keratectomy for correction of astigmatism in corneal grafts. Cornea. 1997;16:48-53. (Pubitemid 27009128)
180. Leccisotti A. Photorefractive keratectomy with mitomycin C after deep anterior lamellar keratoplasty for keratoconus. Cornea. 2008;27: 417-420. (Pubitemid 351591478)
181. Solomon R, Donnenfeld ED, Thimons J, et al. Hyperopic photorefractive keratectomy with adjunctive topical mitomycin C for refractive error after penetrating keratoplasty for keratoconus. Eye Contact Lens. 2004; 30:156-158. (Pubitemid 43196963)
182. Forseto AS, Marques JC, NoséW. Photorefractive keratectomy with mitomycin C after penetrating and lamellar keratoplasty. Cornea. 2010; 29:1103-1108.
183. Qazi MA, Johnson TW, Pepose JS. Development of late-onset subepithelial corneal haze after laser-assisted subepithelial keratectomy with prophylactic intraoperative mitomycin-C: case report and literature review. J Cataract Refract Surg. 2006;32:1573-1578. (Pubitemid 44247487)
184. Mirza MA, Qazi MA, Pepose JS. Treatment of dense subepithelial corneal haze after laser-assisted subepithelial keratectomy. J Cataract Refract Surg. 2004;30:709-714. (Pubitemid 38429651)
185. Shah RA, Wilson SE. Use of mitomycin-C for phototherapeutic keratectomy and photorefractive keratectomy surgery. Curr Opin Ophthalmol. 2010;21:269-273.
186. Kymionis G, Ide T, Yoo S. Flap amputation with phototherapeutic keratectomy (PTK) and adjuvant mitomycin C for severe post-LASIK epithelial ingrowth. Eur J Ophthalmol. 2009;19:301-303.
187. Kim TI, Pak JH, Chae JB, et al. Mitomycin C inhibits recurrent Avellino dystrophy after phototherapeutic keratectomy. Cornea. 2006;25: 220-223. (Pubitemid 43362726)
188. Miller A, Solomon R, Bloom A, et al. Prevention of recurrent Reis- Bücklers dystrophy following excimer laser phototherapeutic keratectomy with topical mitomycin C. Cornea. 2004;23:732-735. (Pubitemid 39314788)
189. Ayres BD, Hammersmith KM, Laibson PR, et al. Phototherapeutic keratectomy with intraoperative mitomycin C to prevent recurrent anterior corneal pathology. Am J Ophthalmol. 2006;142:490-492. (Pubitemid 44691731)